CN115607647A - Application of Anluo chemical fiber composition in preparing anti-fibrosis drugs - Google Patents
Application of Anluo chemical fiber composition in preparing anti-fibrosis drugs Download PDFInfo
- Publication number
- CN115607647A CN115607647A CN202211414094.8A CN202211414094A CN115607647A CN 115607647 A CN115607647 A CN 115607647A CN 202211414094 A CN202211414094 A CN 202211414094A CN 115607647 A CN115607647 A CN 115607647A
- Authority
- CN
- China
- Prior art keywords
- chemical fiber
- volatile oil
- parts
- anluo
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 239000000835 fiber Substances 0.000 title claims abstract description 47
- 239000000126 substance Substances 0.000 title claims abstract description 44
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 230000002300 anti-fibrosis Effects 0.000 title claims abstract description 7
- 229940079593 drug Drugs 0.000 title description 13
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 35
- 241001106477 Paeoniaceae Species 0.000 claims abstract description 34
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 23
- 241000405414 Rehmannia Species 0.000 claims abstract description 13
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims abstract description 7
- 235000003097 Artemisia absinthium Nutrition 0.000 claims abstract description 7
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims abstract description 7
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 7
- 239000001138 artemisia absinthium Substances 0.000 claims abstract description 7
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- 239000000341 volatile oil Substances 0.000 claims description 42
- 239000000284 extract Substances 0.000 claims description 36
- 239000000843 powder Substances 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 22
- 239000000706 filtrate Substances 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 18
- 230000001476 alcoholic effect Effects 0.000 claims description 16
- 238000010298 pulverizing process Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 238000002791 soaking Methods 0.000 claims description 12
- 239000012153 distilled water Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 238000007865 diluting Methods 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 238000007873 sieving Methods 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 230000000536 complexating effect Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 241000092668 Artemisia capillaris Species 0.000 claims description 4
- 235000008658 Artemisia capillaris Nutrition 0.000 claims description 4
- 241000405911 Rehmannia glutinosa Species 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 240000006891 Artemisia vulgaris Species 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 206010019668 Hepatic fibrosis Diseases 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 7
- 240000001851 Artemisia dracunculus Species 0.000 abstract description 6
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 4
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 12
- 208000019425 cirrhosis of liver Diseases 0.000 description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 8
- 102000009027 Albumins Human genes 0.000 description 8
- 108010088751 Albumins Proteins 0.000 description 8
- 229920002674 hyaluronan Polymers 0.000 description 8
- 229960003160 hyaluronic acid Drugs 0.000 description 8
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 8
- 239000012085 test solution Substances 0.000 description 8
- 244000236658 Paeonia lactiflora Species 0.000 description 7
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 7
- 241000700157 Rattus norvegicus Species 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 235000019483 Peanut oil Nutrition 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000000312 peanut oil Substances 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000000702 aorta abdominal Anatomy 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000008576 chronic process Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000008655 huaxian Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the technical field of traditional Chinese medicines, and provides an application of a complex chemical fiber composition in preparing an anti-fibrosis medicine, wherein the complex chemical fiber composition comprises the following components in parts by weight: 8-15 parts of earthworm, 5-10 parts of radix curcumae, 5-10 parts of red paeony root, 5-8 parts of white paeony root, 2-4 parts of oriental wormwood and 2-5 parts of prepared rehmannia root. By the technical scheme, the problem that the hepatic fibrosis inhibition effect of the anti-hepatic fibrosis traditional Chinese medicine in the prior art is slightly poor is solved.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to application of an Anluo chemical fiber composition in preparation of an anti-fibrosis medicine.
Background
Liver fibrosis is a pathological change caused by chronic liver damage caused by various reasons, is represented by excessive deposition of extracellular interstitial components in the liver and influences the function of the liver, and is a stage necessary for the development of chronic liver diseases to cirrhosis. Liver fibrosis is a chronic process, and if effective treatment is performed in an early stage, the liver fibrosis can be reversed to be normal, but if the effective treatment is not obtained, the liver fibrosis can be continuously developed, and then cirrhosis and even liver cancer can be developed. Therefore, treatment should be timely performed when liver fibrosis is found.
The traditional Chinese medicine diagnosis and treatment of hepatic fibrosis lays a basic idea of modern anti-hepatic fibrosis for treating abdominal mass with symptoms under hypochondrium or qi stagnation and blood stasis, activating blood circulation to dissipate blood stasis and specially treating the symptoms under hypochondrium in the famous prescription of the treatise on typhoid infectious diseases. However, although the anti-hepatic fibrosis traditional Chinese medicines on the market can inhibit hepatic fibrosis to a certain extent, the inhibitory effect on hepatic fibrosis still needs to be improved.
Disclosure of Invention
The invention provides application of an Anluo chemical fiber composition in preparing anti-fibrosis drugs, and solves the problem that anti-hepatic fibrosis traditional Chinese medicines in the prior art have a slightly poor inhibition effect on hepatic fibrosis.
The technical scheme of the invention is as follows:
the composition of the Anluo chemical fiber is characterized by comprising the following components in parts by weight:
8-15 parts of earthworm, 5-10 parts of radix curcumae, 5-10 parts of red peony root, 5-8 parts of white peony root, 2-4 parts of oriental wormwood and 2-5 parts of prepared rehmannia root.
The invention also provides a preparation method of the complex chemical fiber composition, which is characterized by comprising the following steps:
s1, adding water into earthworm, radix curcumae and red paeony root, decocting, filtering decoction, and concentrating filtrate into a first extract;
s2, extracting volatile oil from the herba artemisiae scopariae, and diluting the volatile oil with ethanol to obtain an herba artemisiae scopariae volatile oil alcoholic solution;
s3, adding white paeony root into the herba artemisiae scopariae after the volatile oil is extracted, adding water for decocting, filtering decoction, and concentrating filtrate into a second extract;
s4, crushing the prepared rehmannia root into powder to obtain prepared rehmannia root powder;
s5, uniformly mixing the first extract, the capillary artemisia volatile oil alcohol solution, the second extract and the rehmannia glutinosa powder, and drying to obtain the medicinal composition for the collateral-dredging chemical fibers.
As a further technical solution, the S2 specifically is: pulverizing herba Artemisiae Scopariae, sieving with second to third sieves, soaking, distilling to extract volatile oil, and diluting with ethanol to obtain volatile oil alcoholic solution.
According to a further technical scheme, the amount of the distilled water used for soaking in the step S2 is 10 times of the mass of the oriental wormwood, the soaking time is 8 hours, and the distillation time is 5 hours.
As a further technical scheme, the volume ratio of the artemisia capillaris volatile oil to the ethanol in the S2 is 1:3.
as a further technical scheme, the S3 is decocted for 2 times by adding water, and the two decoction liquids are combined and filtered.
The invention also provides a traditional Chinese medicine preparation for Anluo chemical fiber, which is characterized by comprising the Anluo chemical fiber composition or the Anluo chemical fiber medicine composition obtained by the preparation method.
As a further technical scheme, the traditional Chinese medicine preparation for Anluo chemical fiber is pills, tablets, capsules, granules, powder, paste, oral liquid or liquid injection.
The invention also provides application of the complex chemical fiber composition or the complex chemical fiber Chinese medicinal preparation in preparing anti-fibrosis medicaments.
The working principle and the beneficial effects of the invention are as follows:
1. according to the compatibility theory of monarch, minister, assistant and guide in the traditional Chinese medicine, hardness softening and resolving, blood circulation promoting and blood stasis removing, liver and spleen tonifying are used as treatment rules, earthworm, radix curcumae, red paeony root, white paeony root, oriental wormwood and prepared rehmannia root are used as raw materials, earthworm is used as a monarch drug, radix curcumae and red paeony root are used as minister drugs, white paeony root, oriental wormwood and prepared rehmannia root are used as innovative compositions of assistant and guide drugs, and pharmacodynamic tests are utilized to verify the safety and effectiveness of the compositions.
2. According to the invention, the earthworm is taken as a monarch drug, hardness softening and resolving are achieved, the radix curcumae and the red paeony root are taken as ministerial drugs, blood circulation is promoted, stasis is removed, and dry fire is cleared away, and the white paeony root, the herba artemisiae scopariae and the prepared rehmannia root are taken as assistant and guide drugs, so that the liver yin is nourished, and the liver and the spleen are protected. The Anluo Huaxian composition of the invention combines six medicines of earthworm, radix curcumae, red paeony root, white paeony root, oriental wormwood and prepared rehmannia root to play the effect of Anluo Huan and achieve the aim of resisting hepatic fibrosis.
3. According to the invention, the dosage of the adjuvant and conductant medicines of the white paeony root is creatively increased, the white paeony root has the effects of nourishing blood and astringing yin, the red paeony root has the effects of promoting blood circulation and dissipating blood stasis, the white paeony root in the adjuvant and conductant medicines has the effects of reducing diarrhea and supplementing nourishment, and the adjuvant and conductant medicines are combined with each other, so that the anti-hepatic fibrosis effect of the Anluo chemical fiber composition is improved.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any inventive step, are intended to be within the scope of the present invention.
Example 1
The composition of the Anluo chemical fiber is prepared by the following method:
(1) Decocting 15kg of earthworm, 5kg of radix curcumae and 10kg of red paeony root in water, wherein the amount of the water is 5 times of the total mass of the earthworm, the radix curcumae and the red paeony root, filtering the decoction, and concentrating the filtrate until the relative density is 1.15 to obtain a first extract;
(2) Pulverizing herba Artemisiae Scopariae 4kg, sieving with second to third sieves, soaking in 10 times of distilled water for 8 hr, distilling for 5 hr to obtain herba Artemisiae Scopariae volatile oil, and diluting with 3 times of ethanol to obtain herba Artemisiae Scopariae volatile oil alcoholic solution;
(3) Adding 8kg of radix paeoniae alba into the herba artemisiae scopariae after the volatile oil is extracted, adding water for decocting for 2 times, wherein the amount of water used in each time is 10 times of the mass of the radix paeoniae alba, combining the decoctions for filtering, and concentrating the filtrate until the relative density is 1.2 to obtain a second extract;
(4) Pulverizing 2kg radix rehmanniae Preparata into powder to obtain radix rehmanniae Preparata powder;
(5) Mixing the first extract, the volatile oil alcoholic solution of herba Artemisiae Scopariae, the second extract, and radix rehmanniae Preparata powder, and drying to obtain the composition.
Example 2
The composition of the Anluo chemical fiber is prepared by the following method:
(1) Decocting 10kg of earthworm, 7kg of radix curcumae and 5kg of red paeony root in water, wherein the amount of the water is 5 times of the total mass of the earthworm, the radix curcumae and the red paeony root, filtering the decoction, and concentrating the filtrate until the relative density is 1.15 to obtain a first extract;
(2) Taking 2kg of herba artemisiae scopariae, crushing the herba artemisiae scopariae, sieving the herba artemisiae scopariae by a sieve from No. two to No. three, soaking the herba artemisiae scopariae for 8 hours by using distilled water with the mass being 10 times of the weight of the herba artemisiae scopariae, then distilling and extracting the herba artemisiae scopariae for 5 hours to obtain herba artemisiae scopariae volatile oil, and adding ethanol with the volume being 3 times of the volume of the herba artemisiae scopariae volatile oil to dilute the herba artemisiae scopariae volatile oil to obtain an herba artemisiae scopariae volatile oil alcoholic solution;
(3) Adding 7kg of radix paeoniae alba into the herba artemisiae scopariae after the volatile oil is extracted, adding water for decocting for 2 times, wherein the amount of the water is 10 times of the mass of the radix paeoniae alba, combining the decoctions for two times, filtering, and concentrating the filtrate until the relative density is 1.2 to obtain a second extract;
(4) Pulverizing 3kg radix rehmanniae Preparata into powder to obtain radix rehmanniae Preparata powder;
(5) Mixing the first extract, the volatile oil alcoholic solution of herba Artemisiae Scopariae, the second extract, and radix rehmanniae Preparata powder, and drying to obtain the composition.
Example 3
The Anluo chemical fiber composition is prepared by the following method:
(1) Decocting 8kg of earthworm, 5kg of radix curcumae and 5kg of red paeony root in water, wherein the amount of the water is 5 times of the total mass of the earthworm, the radix curcumae and the red paeony root, filtering decoction, and concentrating filtrate until the relative density is 1.15 to obtain a first extract;
(2) Pulverizing 3kg herba Artemisiae Scopariae, sieving with No. two to No. three sieve, soaking in 10 times of distilled water for 8 hr, distilling for 5 hr to obtain herba Artemisiae Scopariae volatile oil, and diluting with 3 times of ethanol to obtain herba Artemisiae Scopariae volatile oil alcoholic solution;
(3) Adding 5kg of white peony root into the herba artemisiae scopariae after the volatile oil is extracted, adding water, decocting for 2 times, wherein the amount of water used in each time is 10 times of the mass of the white peony root, combining the decoctions obtained in two times, filtering, and concentrating the filtrate until the relative density is 1.2 to obtain a second extract;
(4) Pulverizing 5kg radix rehmanniae Preparata into powder to obtain radix rehmanniae Preparata powder;
(5) Mixing the first extract, the volatile oil alcoholic solution of herba Artemisiae Scopariae, the second extract, and radix rehmanniae Preparata powder, and drying to obtain the composition.
Example 4
The composition of the Anluo chemical fiber is prepared by the following method:
(1) Decocting 12kg of earthworm, 10kg of radix curcumae and 5kg of red paeony root in water, wherein the amount of the water is 5 times of the total mass of the earthworm, the radix curcumae and the red paeony root, filtering decoction, and concentrating filtrate until the relative density is 1.15 to obtain a first extract;
(2) Pulverizing 2kg of herba Artemisiae Scopariae, sieving with No. two-No. three sieve, soaking in 10 times of distilled water for 8 hr, distilling for 5 hr to obtain herba Artemisiae Scopariae volatile oil, and diluting with 3 times of ethanol to obtain herba Artemisiae Scopariae volatile oil alcoholic solution;
(3) Adding 5kg of white peony root into the herba artemisiae scopariae after the volatile oil is extracted, adding water, decocting for 2 times, wherein the amount of water used in each time is 10 times of the mass of the white peony root, combining the decoctions obtained in two times, filtering, and concentrating the filtrate until the relative density is 1.2 to obtain a second extract;
(4) Pulverizing 2kg radix rehmanniae Preparata into powder to obtain radix rehmanniae Preparata powder;
(5) Mixing the first extract, the volatile oil alcoholic solution of herba Artemisiae Scopariae, the second extract, and radix rehmanniae Preparata powder, and drying to obtain the composition.
Example 5
The Anluohuaxianhua capsule is prepared with the following steps:
4.5kg of the Anluo chemical fiber pharmaceutical composition prepared in example 1 is taken, made into soft material by 85% ethanol, granulated by a 16-mesh sieve, dried at 60 ℃, granulated by a 14-mesh sieve, filled into a No. 0 capsule according to 0.4 g/capsule, polished, inspected and packaged to obtain 11075 Anluo chemical fiber capsules.
Example 6
The Anluohuaxianwan pill is prepared by the following steps:
4.5kg of the medicinal composition of Anluo chemical fiber prepared in example 1 is taken, crushed and sieved by a 100-mesh sieve, and refined honey is added to prepare pills, wherein the weight of each pill is 0.5g, so that Anluo chemical fiber pills are obtained.
Comparative example 1
The Anluo chemical fiber composition is prepared by the following method:
(1) Decocting 15kg of earthworm, 5kg of radix curcumae and 10kg of red paeony root in water, wherein the amount of the water is 5 times of the total mass of the earthworm, the radix curcumae and the red paeony root, filtering the decoction, and concentrating the filtrate until the relative density is 1.15 to obtain a first extract;
(2) Pulverizing 4kg herba Artemisiae Scopariae, sieving with No. two to No. three sieve, soaking in 10 times of distilled water for 8 hr, distilling for 5 hr to obtain herba Artemisiae Scopariae volatile oil, and diluting with 3 times of ethanol to obtain herba Artemisiae Scopariae volatile oil alcoholic solution;
(3) Adding 3kg of radix paeoniae alba into the herba artemisiae scopariae after the volatile oil is extracted, adding water for decocting for 2 times, wherein the amount of the water is 10 times of the mass of the radix paeoniae alba, combining the decoctions for two times, filtering, and concentrating the filtrate until the relative density is 1.2 to obtain a second extract;
(4) Pulverizing 2kg radix rehmanniae Preparata into powder to obtain radix rehmanniae Preparata powder;
(5) Mixing the first extract, the volatile oil alcoholic solution of herba Artemisiae Scopariae, the second extract, and radix rehmanniae Preparata powder, and drying to obtain the composition.
Comparative example 2
The composition of the Anluo chemical fiber is prepared by the following method:
(1) Decocting 15kg of earthworm, 5kg of radix curcumae and 10kg of red paeony root in water, wherein the amount of the water is 5 times of the total mass of the earthworm, the radix curcumae and the red paeony root, filtering the decoction, and concentrating the filtrate until the relative density is 1.15 to obtain a first extract;
(2) Decocting 4kg of herba Artemisiae Scopariae and 5kg of radix Paeoniae alba in water for 2 times, wherein the amount of water is 10 times of the total weight of herba Artemisiae Scopariae and radix Paeoniae alba, mixing the decoctions, filtering, and concentrating the filtrate to relative density of 1.2 to obtain a second extract;
(3) Pulverizing 2kg radix rehmanniae Preparata into powder to obtain radix rehmanniae Preparata powder;
(4) And uniformly mixing the first extract, the second extract and the rehmannia root powder of rehmannia, and drying to obtain the medicinal composition of the Anluo chemical fiber.
Comparative example 3
Anluo chemical fiber composition prepared by the following method
(1) Decocting 15kg of earthworm, 5kg of radix curcumae and 10kg of red paeony root in water, wherein the amount of the water is 5 times of the total mass of the earthworm, the radix curcumae and the red paeony root, filtering decoction, and concentrating the filtrate until the relative density is 1.15 to obtain a first extract;
(2) Pulverizing 4kg herba Artemisiae Scopariae, sieving with No. two to No. three sieve, soaking in 10 times of distilled water for 8 hr, distilling for 5 hr to obtain herba Artemisiae Scopariae volatile oil, and diluting with 3 times of ethanol to obtain herba Artemisiae Scopariae volatile oil alcoholic solution;
(3) Adding 10kg of white peony root into the herba artemisiae scopariae after the volatile oil is extracted, adding water, decocting for 2 times, wherein the amount of water used in each time is 10 times of the mass of the white peony root, combining the decoctions obtained in two times, filtering, and concentrating the filtrate until the relative density is 1.2 to obtain a second extract;
(4) Pulverizing 2kg radix rehmanniae Preparata into powder to obtain radix rehmanniae Preparata powder;
(5) Mixing the first extract, the volatile oil alcoholic solution of herba Artemisiae Scopariae, the second extract, and radix rehmanniae Preparata powder, and drying to obtain the composition.
Pharmacodynamic experiment:
experiment I, rat hepatic fibrosis model treatment
1. Experimental materials:
(1) Experimental animals: wistar rats 100 female, weighing 180-230g, were provided by the Experimental animals center of North river university of medicine. The rats are bred according to the clean grade standard, and are bred adaptively for one week before the experiment is formally started.
(2) Experimental drugs: the complexing fiber compositions of the embodiment 1 and the comparative examples 1 to 3 are divided into a low-dose group, a medium-dose group and a high-dose group, the complexing fiber compositions of the comparative examples 1 to 3 only have the high-dose group, before the experiment, distilled water is added into the complexing fiber compositions of the groups to prepare test solutions, the concentration of the low-dose test solution is 0.06g/mL, the concentration of the medium-dose test solution is 0.12g/mL, and the concentration of the high-dose test solution is 0.24g/mL.
(3) The experimental reagent: carbon tetrachloride (CCl) 4 ) And analyzing and purifying; peanut oil: edible peanut oil of Gonglongyu brand; according to CCl 4 Is prepared into CCl with peanut oil according to the volume ratio of 2 4 The suspension is ready for use.
2. Experimental methods
(1) Experimental modelling
Adaptively feeding 100 female Wistar rats for one week, randomly dividing the rats into a blank group and a model group, wherein the blank group comprises 10 rats, the model group comprises 90 female Wistar rats, the first dose is 0.5mL/100g of body weight, and injecting CCl into the abdominal cavity of the rats 4 Suspending the solution, and performing intraperitoneal injection once every 3 days, wherein the later dose is 0.3mL/100g of body weight; a blank group of 10 female Wistar rats and a model group are injected with peanut oil with equal dosage in the abdominal cavity at the same time, during the experiment period, all rats are fed with common feed and drink water freely, and the experiment lasts for 6 weeks; in the experimental process, 3 female Wistar rats die in total in the model group; 1 female Wistar rat was sacrificed randomly from the model group every week starting at the end of week 4, pathological changes of liver were observed under an optical microscope, and the results of observation at the end of week 6 confirmed that the hepatic fibrosis model of rat was successfully modeled.
(2) Experiment grouping
The remaining 84 female Wistar rats in the model group were randomly divided into 7 groups of 12 rats each; respectively a low-dose experiment group, a medium-dose experiment group, a high-dose control 1 group, a high-dose control 2 group, a high-dose control 3 group and a model control group; wherein, the rats of the low-dose experiment group, the medium-dose experiment group and the high-dose experiment group are respectively drenched and implementedRats of the low-dose test solution, the medium-dose test solution and the high-dose test solution of example 1, the high-dose control group 2 and the high-dose control group 3 were respectively drenched with the high-dose test solution of comparative examples 1-3, and the blank group and the model control group were drenched with distilled water; the dosage is 0.2mL/100g body weight, and the administration is started from 7 weeks and performed by intragastric administration for 1 time every day until the end of 12 weeks; and from week 7 to week 12, the model group was still intraperitoneally injected with CCl once a week 4 Suspending the solution, and the dosage is 0.3mL/100g body weight.
(3) Specimen extraction
After the last administration at the end of week 12, the rats are fasted overnight, the rats in each group are anesthetized by injecting 10% chloral hydrate into the abdominal cavity after weighing the rats the next day, the dosage is 0.4mL/100g of body weight, then the skin is cut from the median line of the abdomen and enters the abdominal cavity, the abdominal aorta is separated, blood is collected through the abdominal aorta, the abdominal aorta is kept still for half an hour and then centrifuged at 3000r/min for 10min, serum is collected and is stored in a refrigerator at the temperature of-80 ℃ for testing.
(4) Experimental detection
Detecting glutamic-oxaloacetic transaminase (AST), glutamic-pyruvic transaminase (ALT) and Albumin (ALB) in rat serum by using a full-automatic biochemical analyzer; detecting rat serum Hyaluronic Acid (HA), procollagen type (PC-III), collagen type (IV-C) and Laminin (LN) by adopting an immunoassay; the detection method is carried out according to the method in the kit instruction; the experimental results were statistically analyzed using SPSS.
3. Results of the experiment
(1) Influence of Anluo chemical fiber composition on AST, ALT and ALB of liver fibrosis rat serum
The results are shown in table 1:
TABLE 1 influence of Anluo chemical fiber composition on AST, ALT and ALB serum of hepatic fibrosis rat
| Group of | AST(U/L) | ALT(U/L) | ALB(g/L) |
| Blank group | 61.58±11.07 | 49.71±12.36 | 29.27±8.65 |
| Model control group | 193.26±39.45** | 113.44±31.69** | 19.76±6.47** |
| Low dose test group | 85.51±15.66* | 68.76±16.53* | 22.33±4.39** |
| Middle dose test group | 67.74±11.23* | 53.42±13.38 | 28.05±5.86 |
| High dose test group | 60.36±10.72 | 50.61±11.55 | 29.43±8.92 |
| High dose control 1 group | 86.74±19.22** | 71.46±17.72* | 24.66±7.73* |
| High dose control 2 group | 109.28±20.16** | 83.65±19.28** | 21.35±6.49** |
| High dose control 3 groups | 79.45±15.53** | 73.22±16.64* | 22.47±7.15** |
Note: without belts * Indicating that the group data was not significantly different from the blank group (P > 0.05), * indicating that the group data is significantly different (0.01 < P < 0.05) compared with the blank group, ** this data showed very significant variability (P < 0.01) compared to the blank.
The data in the table show that the differences of the serum ALT and ALB of the mice in the middle-dose experimental group and the blank group are not obvious, and the differences of the serum AST, ALT and ALB of the mice in the high-dose experimental group and the blank group are not obvious, which shows that the composition of the invention in the embodiment 1 can have good therapeutic effect on the mice with hepatic fibrosis when the composition is used in high dose, and can make the serum AST, ALT and ALB of the treated mice return to normal.
(2) Influence of Anluo chemical fiber composition on liver fibrosis rat serum HA, PC-III, IV-C and LN
The results are shown in table 2:
TABLE 2 influence of the composition of Anluo chemical fiber on the serum HA, PC-III, IV-C, LN of rats with hepatic fibrosis
Note: without belts * Indicating that the group data was not significantly different from the blank group (P > 0.05), * indicating that the group data is significantly different (0.01 < P < 0.05) compared with the blank group, ** this data showed a very significant difference (P < 0.01) from the blank.
The data in the table show that the differences of the mouse serum HA, PC-III and LN of the medium-dose experimental group and the blank group are not significant, and the differences of the mouse serum HA, PC-III, IV-C and LN of the high-dose experimental group and the blank group are not significant, which shows that the composition of the invention in the embodiment 1 can have good therapeutic effect on the mouse serum HA, PC-III, IV-C and LN of hepatic fibrosis when the composition is used in high dose, and can make the serum HA, PC-III, IV-C and LN of the treated mice return to normal.
The present invention is not limited to the above preferred embodiments, and any modifications, equivalent substitutions, improvements, etc. within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (9)
1. The composition of the Anluo chemical fiber is characterized by comprising the following components in parts by weight:
8-15 parts of earthworm, 5-10 parts of radix curcumae, 5-10 parts of red paeony root, 5-8 parts of white paeony root, 2-4 parts of oriental wormwood and 2-5 parts of prepared rehmannia root.
2. The method for preparing the complex chemical fiber composition according to claim 1, comprising the following steps:
s1, adding water into earthworm, radix curcumae and red paeony root, decocting, filtering decoction, and concentrating filtrate into a first extract;
s2, extracting volatile oil from the herba artemisiae scopariae, and diluting the volatile oil with ethanol to obtain an herba artemisiae scopariae volatile oil alcoholic solution;
s3, adding white paeony root into the herba artemisiae scopariae after the volatile oil is extracted, adding water for decocting, filtering decoction, and concentrating filtrate into a second extract;
s4, crushing the prepared rehmannia root into powder to obtain prepared rehmannia root powder;
s5, uniformly mixing the first extract, the capillary artemisia volatile oil alcohol solution, the second extract and the rehmannia glutinosa powder, and drying to obtain the medicinal composition for the collateral-dredging chemical fibers.
3. The preparation method of the complex chemical fiber composition according to claim 2, wherein the S2 is specifically: pulverizing herba Artemisiae Scopariae, sieving with second to third sieves, soaking, distilling to extract volatile oil, and diluting with ethanol to obtain volatile oil alcoholic solution.
4. The method for preparing the complexing chemical fiber composition according to claim 3, wherein the amount of distilled water used for soaking in S2 is 10 times of the weight of herba Artemisiae Scopariae, the soaking time is 8 hours, and the distilling time is 5 hours.
5. The method for preparing the complexing chemical fiber composition of claim 3, wherein the volume ratio of the artemisia capillaris volatile oil to the ethanol in the S2 is 1:3.
6. the method for preparing the composition of the andros chemical fiber according to claim 2, wherein the water is added into the S3 for 2 times of decoction, and the two decoctions are combined and filtered.
7. A traditional Chinese medicine preparation for Anluo chemical fiber, which is characterized by comprising the Anluo chemical fiber composition of claim 1 or the Anluo chemical fiber pharmaceutical composition obtained by the preparation method of any one of claims 2 to 6.
8. The traditional Chinese medicine preparation for Anluo chemical fiber according to claim 7, wherein the traditional Chinese medicine preparation for Anluo chemical fiber is a pill, a tablet, a capsule, a granule, a powder, an ointment, an oral liquid or a liquid injection.
9. The use of the composition of claim 1 or the Chinese medicinal preparation of Anluohuaxianhua according to any one of claims 7-8 in the preparation of anti-fibrosis medicaments.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211414094.8A CN115607647B (en) | 2022-11-11 | 2022-11-11 | Application of Anluo chemical fiber composition in preparation of anti-fibrosis drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211414094.8A CN115607647B (en) | 2022-11-11 | 2022-11-11 | Application of Anluo chemical fiber composition in preparation of anti-fibrosis drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115607647A true CN115607647A (en) | 2023-01-17 |
| CN115607647B CN115607647B (en) | 2024-02-02 |
Family
ID=84878037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211414094.8A Active CN115607647B (en) | 2022-11-11 | 2022-11-11 | Application of Anluo chemical fiber composition in preparation of anti-fibrosis drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115607647B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1273832A (en) * | 2000-05-09 | 2000-11-22 | 黄志荣 | Compound Yexiazhu medicine and preparing process thereof |
| CN1795896A (en) * | 2004-12-24 | 2006-07-05 | 同济大学 | Medication for curing hepatic fibrosis and hepatic cirrhosis, and prepartion method |
| CN103028092A (en) * | 2012-12-28 | 2013-04-10 | 李瀚旻 | Medicine for regulating liver regeneration and preparation method of medicine |
| CN109200126A (en) * | 2017-06-29 | 2019-01-15 | 洪铁 | A kind of Chinese medicine composition that treating liver fibrosis and its application |
| CN113350454A (en) * | 2021-06-16 | 2021-09-07 | 森隆药业有限公司 | Application of Anluo chemical fiber composition in preparation of medicine for preventing or treating hepatic fibrosis |
-
2022
- 2022-11-11 CN CN202211414094.8A patent/CN115607647B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1273832A (en) * | 2000-05-09 | 2000-11-22 | 黄志荣 | Compound Yexiazhu medicine and preparing process thereof |
| CN1795896A (en) * | 2004-12-24 | 2006-07-05 | 同济大学 | Medication for curing hepatic fibrosis and hepatic cirrhosis, and prepartion method |
| CN103028092A (en) * | 2012-12-28 | 2013-04-10 | 李瀚旻 | Medicine for regulating liver regeneration and preparation method of medicine |
| CN109200126A (en) * | 2017-06-29 | 2019-01-15 | 洪铁 | A kind of Chinese medicine composition that treating liver fibrosis and its application |
| CN113350454A (en) * | 2021-06-16 | 2021-09-07 | 森隆药业有限公司 | Application of Anluo chemical fiber composition in preparation of medicine for preventing or treating hepatic fibrosis |
Non-Patent Citations (2)
| Title |
|---|
| 陈一凡等: "" 茵陈 — 郁金 " 药对配伍 对肝纤维化模型大鼠作用效果研究", 贵阳中医学院学报, vol. 40, no. 2, pages 13 - 15 * |
| 齐洪军 , 胡曼菁 , 王长松 , 刘顺英: ""祛瘀化痰汤"抗大鼠肝纤维化的作用及其机制", 江苏中医药, vol. 24, no. 07, pages 55 - 57 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115607647B (en) | 2024-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1899361A (en) | Zhenqi medicinal composition and its preparation | |
| KR101088539B1 (en) | Chinese medicinal compositions for treating headache, formulations and processes for preparation therof | |
| CN1947757B (en) | Leave of glutinous rehmannia extractive, its preparation method and use, medicines prepared with said extractives | |
| CN106822579B (en) | Composition with osteoporosis treatment effect and preparation method and application thereof | |
| CN1038585A (en) | Clear away heart-fire liquid and preparation method thereof | |
| CN115607647A (en) | Application of Anluo chemical fiber composition in preparing anti-fibrosis drugs | |
| CN110123974A (en) | A kind of composition that treating hyperuricemia and preparation method | |
| TWI517857B (en) | A pharmaceutical composition for treating senile dementia and a preparation method thereof | |
| CN107485615A (en) | Purposes of the Ligustrum robust glycosides C and combinations thereof in treatment hyperlipidemia and slimming medicine is prepared | |
| CN100479837C (en) | Weinakang for treating ischemic cerebrovascular disease and senile dementia and preparation method thereof | |
| CN1686424A (en) | Medicinal composition containing scutellaria and bupleurum and its preparation method | |
| CN100400053C (en) | Bupleurum root soft capsule and its preparation method | |
| CN1824016A (en) | Compound flowery knotweed and rehmannia preparation and its manufacturing method | |
| CN1775247A (en) | Fleece-flower root and rhizoma rehmanniae preparation and new preparing method | |
| CN1712060A (en) | Preparation of Chinese medicinal mixture for treating gynecologic menstrual disease | |
| JP2005194256A (en) | Hepatic disease-treating medicinal composition and method for producing the same | |
| CN1079396A (en) | Intelligence-enhancing pharmaceutical preparation | |
| CN106177350B (en) | Purposes of the Resina Draconis phenols extract in the drug that preparation improves renal function | |
| Punegov et al. | Extraction of ecdysteron-80 from Serratula coronata L. and assessment of its pharmacological action. Part I. Adaptogenic, gastroprotective, thermoprotective, and antihypoxic activity. | |
| CN115025191B (en) | A Chinese medicinal composition for invigorating kidney and spleen, nourishing blood, and calming heart, and its preparation method | |
| CN1150918C (en) | Medicine containing active components of Panax japonicum root and preparing process thereof | |
| CN110420264B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN1579520A (en) | Preparation for eliminating thrombus and promoting lactation, and its preparation method | |
| CN107693618B (en) | Pharmaceutical composition for treating kidney deficiency and preparation method and application thereof | |
| CN101045099B (en) | Traditional Chinese medicine composition for treating high fever tic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |